Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.

Zhang, Zewei; Xie, Chunxia; Gao, Tiantian; Yang, Yuxian; Yang, Yong; Zhao, Lei

Zhang, Zewei; Xie, Chunxia; Gao, Tiantian; Yang, Yuxian; Yang, Yong; Zhao, Lei.

Afiliación

Zhang Z; Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Xie C; State Key Laboratory of Oncology in South China, Guangzhou, China.
Gao T; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yang Y; Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Yang Y; State Key Laboratory of Oncology in South China, Guangzhou, China.
Zhao L; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

BMC Cancer ; 23(1): 145, 2023 Feb 10.

Article en En | MEDLINE | ID: mdl-36765311

Asunto(s)

Neoplasias Esofágicas; Carcinoma de Células Escamosas de Esófago; Humanos; Supervivencia sin Progresión; Antígeno B7-H1; Carcinoma de Células Escamosas de Esófago/tratamiento farmacológico; Teorema de Bayes; Neoplasias Esofágicas/tratamiento farmacológico; Estudios Retrospectivos; Biomarcadores; Inmunoterapia/métodos

Palabras clave

Advanced esophageal squamous cell carcinoma; PD-1/PD-L1 inhibitors; Progression-free survival; Surrogate

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas de Esófago Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google